Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: many blockbusters to fade this year: semaglutide’s India reckoning; multinationals look beyond simple China licensing; Almirall eyes China dermatology assets; EU urged to restore biopharma competitiveness.
Scrip - March 23, 2026

Screenless, Smartphone-Controlled Pump: MiniMed Flex Cleared By FDA Weeks After IPO
After its IPO, MiniMed has its first FDA clearance as a public company. The MiniMed Flex – smaller, screenless, and smartphone-controlled – is the product the newly independent diabetes firm needed to shift the conversation from market debut to market execution.
Medtech Insight - March 20, 2026

Verily Raises $300M To Advance Precision Health Platform As Independent Firm
Google spinout Verily has raised $300m to advance its AI-driven personalized healthcare platforms and become an independent company.
Medtech Insight - March 20, 2026

NICE To Reassess English Funding Rejections Of Leqembi And Kisunla After Successful Appeals
According to the health technology assessment institute, NICE, new cost-effectiveness thresholds – which are higher than those that applied when the original decisions were made – will apply when its committee reconsiders the appraisals for Eisai and Eli Lilly’s Alzheimer’s disease drugs.
Pink Sheet - March 20, 2026

MEPs Vote To Delay And Simplify AI Act Rules For Medical Devices
In an effort to streamline AI rules for high-risk systems and improve competitiveness, two European Parliament committees agreed amendments to the EU AI Act that will allow medtech companies to avoid double certification with notified bodies. A plenary vote takes place in late March.
Medtech Insight - March 20, 2026

PDUFA VIII: US FDA Tries To Resolve ‘America First’ Impasse
Agency offered to drop annual IND fees for sponsors not conducting Phase I trials in US, but industry still raised several concerns about fee incentives for onshoring clinical development.
HBW Insight - March 23, 2026

Consumer Healthcare M&A, Investment Advisor Receives CHPA Lifetime Achievement Award
At opening session of CHPA’s annual Self-Care Leadership Summit on March 17 in Orlando, it presented Fuad Sawaya its highest honor named for Ivan Combe, an industry pioneer who served on its board from 1958 until 2000.
HBW Insight - March 23, 2026

Natco’s 90% Semaglutide Discount Sets Price Expectations In India
Natco has announced a 90% difference in the price of its semaglutide generic in multi-dose vials versus originator Novo Nordisk’s Ozempic pen ahead of launch tomorrow, as Novo’s patents on the product expire today. Its pen will be 70% cheaper.
Generics Bulletin - March 20, 2026

Iran War Could Threaten Long-Term Industry Sustainability
Amid “significant uncertainty” for the off-patent industry caused by the war in Iran, the IGBA has warned that a prolonged conflict “could make solvent supply a critical concern” while escalating costs and squeezed margins could affect the long-term sustainability of affordable medicines.
Generics Bulletin - March 20, 2026

Alvotech Pivots To Dual Sourcing Amid Regulatory Reset
Alvotech is shifting toward dual-source manufacturing and operational execution as it addresses FDA setbacks, expands its biosimilar pipeline and drives growth through global launches, with US approvals representing key upside to its 2026 outlook.
Generics Bulletin - March 20, 2026

Formycon Unlocks Global Markets For Its Eylea Biosimilar
Formycon expects its aflibercept biosimilar to enter European markets from the end of spring, as commercial paths also open up in Latin America and Asia Pacific countries.
Generics Bulletin - March 20, 2026

Execs On The Move: February 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - March 18, 2026

Adapt To Survive: Private Hospitals In A High-Pressure Landscape
Payers' and patients' growing preference for outpatient care is increasing pressure on private providers to continually reassess how they deliver value. Jean-Philippe Grosmaitre and Guillaume Duparc, partners at L.E.K. Consulting, outlined growth opportunities available to private hospitals.
In Vivo - March 18, 2026

An Irregular Regulatory Agency: Industry Contends With An Unpredictable FDA
A series of surprise rejections has made for an FDA that drug and vaccine manufacturers are finding much harder to read than in years past.
In Vivo - March 18, 2026